SANUWAVE Health, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
May 09, 2024 at 04:54 pm
Share
SANUWAVE Health, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was USD 5.79 million compared to USD 3.78 million a year ago. Net loss was USD 4.53 million compared to USD 13.08 million a year ago.
Sanuwave Health, Inc. is an ultrasound and shock wave technology company. The Company is a provider of Food and Drug Administration (FDA)-approved wound care products. It is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. The Company applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and others. Its two primary systems are UltraMIST and PACE. The UltraMIST system provides, through a fluid mist, low-frequency, non-contact, and pain free ultrasound energy deep inside the wound bed that promotes healing from within. The PACE systems use acoustic pressure shockwaves generated by the Company's Pulsed Acoustic Cellular Expression (PACE) technology to converge at precise selected targets to produce an extremely short duration compression burst.